Aurobindo Pharma (AUROPHARMA) — Board Meeting

📢 Key Event
Aurobindo Pharma's 39th AGM approved FY2025-26 financials and reappointed directors.

🔄 What Changed
Reappointment of directors and adoption of audited financial statements.

🔮 What's Next
Results to be filed with exchanges within two working days post-AGM.

💡 Investor Takeaway
Shareholders approved key financials and leadership continuity, signaling stability.

Aurobindo Pharma held its 39th AGM on August 27, 2026, via video conferencing, adopting audited standalone and consolidated financial statements for FY2025-26, confirming a Rs.4 interim dividend per share, and reappointing directors K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy. Shareholders participated electronically, with voting open from August 24-26, 2026, and results to be filed with exchanges within two working days.

📄 View Original Announcement (PDF)

📊 Stock Analysis — AUROPHARMA ✨ Ask AI About This

About Aurobindo Pharma Ltd (AUROPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹97,238.86 Cr P/E: 26.4 ROE: 9.8% ROCE: 12.8% Div Yield: 0.24%

View full AUROPHARMA stock details →

📡 Get AI alerts when AUROPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AUROPHARMA — Free

💡 Ask AI about this filing

"What were the FY2025-26 revenue and profit figures?" "How does the interim dividend compare to previous years?" "What is the outlook for international market expansion?"

Ask AI Free →

📊 More AUROPHARMA filings

See all AUROPHARMA filings →

🔥 Also filed on 27 August 2026

JNPR Juniper Green Energy Ltd Financial Results AWFIS AWFIS Space Solutions Ltd Annual Report 509084 Photon Capital Advisors Ltd Annual Report GUJALKALI Gujarat Alkalies & Chemicals Ltd Annual Report EPACK Epack Durable Ltd Annual Report 538546 Bansal Roofing Products Ltd Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AUROPHARMA files new disclosures

Track AUROPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AUROPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd